Dragonfly Therapeutics and AbbVie have expanded their research partnership for the discovery and development of the former’s novel immunotherapies for new targets in fibrotic and autoimmune diseases. In January last year, AbbVie had licenced its […]
Opus Genetics and National Resilience have signed a strategic manufacturing services agreement for developing and manufacturing the former’s adeno-associated viral (AAV) vector-based gene therapies for inherited retinal diseases (IRD). Under the partnership, Resilience will offer […]
Eisai has reported that its therapy Lenvima (lenvatinib mesylate) obtained approval in Taiwan to treat advanced endometrial carcinoma patients along with Merck’s (MSD) Keytruda (pembrolizumab). An orally available inhibitor of multiple receptor tyrosine kinase, Lenvima […]
Code Biotherapeutics and Takeda have entered a partnership and option agreement for designing and developing gene therapies to treat rare diseases. The targeted 3DNA non-viral genetic medicine delivery platform of Code Bio will be used […]
Screening for premalignant precursor conditions could serve as an important step in the early detection and treatment of multiple myeloma. However, more insights are needed to determine the optimal criteria for screening programs, experts say, […]